OBJECTIVE: Although co-occurring psychiatric disorders are highly prevalent among those with HIV, little is known about the use of outpatient mental health services (MHS) and psychotropic medication in the highly active antiretroviral therapy (HAART) era. METHODS: During 2003, 951 patients were interviewed at 14 sites in the HIV Research Network. Patients were questioned about use of MHS and psychotropic medications. Logistic regression was used to identify socio-demographic and clinical factors associated with MHS and psychotropic medication utilization. RESULTS: The sample characteristics were as follows: 68% male, 52% black, 14% Hispanic, median age 46 years (range 20-85), 69% were on HAART. Approximately 34% reported at least one MHS within 6 months and 37% reported use of psychotropic medication for a mental health condition. In multivariate logistic regression, MHS was greater among disabled patients [adjusted odds ratio 2.39 (95% CI 1.53-3.72)], current [2.26 (1.53-3.35)] and former drug users [1.84 (1.24-2.73)], and those with more than seven primary care visits in the past 6 months. Blacks [0.61 (0.41-0.92)] were significantly less likely to use MHS compared to whites. Similarly, usage of psychotropic medications was greater among disabled patients [1.79 (1.14-2.82)], women [1.66 (1.13-2.43)], )] and those with more than seven primary care visits. Blacks [0.37 (0.24-0.58])] and Hispanics [0.39 (0.22-0.72)] were less likely to use a psychotropic medication. HAART utilization was not associated with MHS or psychiatric medication use. CONCLUSIONS: In the HAART era, self-reported rates of mental health service and psychotropic medication utilization are high. Blacks continue to report lower use of MHS and psychotropic medication compared to whites.
OBJECTIVE: Although co-occurring psychiatric disorders are highly prevalent among those with HIV, little is known about the use of outpatient mental health services (MHS) and psychotropic medication in the highly active antiretroviral therapy (HAART) era. METHODS: During 2003, 951 patients were interviewed at 14 sites in the HIV Research Network. Patients were questioned about use of MHS and psychotropic medications. Logistic regression was used to identify socio-demographic and clinical factors associated with MHS and psychotropic medication utilization. RESULTS: The sample characteristics were as follows: 68% male, 52% black, 14% Hispanic, median age 46 years (range 20-85), 69% were on HAART. Approximately 34% reported at least one MHS within 6 months and 37% reported use of psychotropic medication for a mental health condition. In multivariate logistic regression, MHS was greater among disabled patients [adjusted odds ratio 2.39 (95% CI 1.53-3.72)], current [2.26 (1.53-3.35)] and former drug users [1.84 (1.24-2.73)], and those with more than seven primary care visits in the past 6 months. Blacks [0.61 (0.41-0.92)] were significantly less likely to use MHS compared to whites. Similarly, usage of psychotropic medications was greater among disabled patients [1.79 (1.14-2.82)], women [1.66 (1.13-2.43)], )] and those with more than seven primary care visits. Blacks [0.37 (0.24-0.58])] and Hispanics [0.39 (0.22-0.72)] were less likely to use a psychotropic medication. HAART utilization was not associated with MHS or psychiatric medication use. CONCLUSIONS: In the HAART era, self-reported rates of mental health service and psychotropic medication utilization are high. Blacks continue to report lower use of MHS and psychotropic medication compared to whites.
Authors: Frank H Galvan; Eric G Bing; John A Fleishman; Andrew S London; Raul Caetano; M Audrey Burnam; Doug Longshore; Sally C Morton; Maria Orlando; Martin Shapiro Journal: J Stud Alcohol Date: 2002-03
Authors: M A Burnam; E G Bing; S C Morton; C Sherbourne; J A Fleishman; A S London; B Vitiello; M Stein; S A Bozzette; M F Shapiro Journal: Arch Gen Psychiatry Date: 2001-08
Authors: Mark Olfson; Steven C Marcus; Benjamin Druss; Lynn Elinson; Terri Tanielian; Harold Alan Pincus Journal: JAMA Date: 2002-01-09 Impact factor: 56.272
Authors: Benedetto Vitiello; M Audrey Burnam; Eric G Bing; Robin Beckman; Martin F Shapiro Journal: Am J Psychiatry Date: 2003-03 Impact factor: 18.112
Authors: Judith A Cook; Mardge H Cohen; Jane Burke; Dennis Grey; Kathryn Anastos; Lynn Kirstein; Herminia Palacio; Jean Richardson; Tracey Wilson; Mary Young Journal: J Acquir Immune Defic Syndr Date: 2002-08-01 Impact factor: 3.731
Authors: B J Turner; J A Fleishman; N Wenger; A S London; M A Burnam; M F Shapiro; E G Bing; M D Stein; D Longshore; S A Bozzette Journal: J Gen Intern Med Date: 2001-09 Impact factor: 5.128
Authors: Angela M Bengtson; Brian W Pence; Richard Moore; Matthew J Mimiaga; William Christopher Mathews; Amy Heine; Bradley N Gaynes; Sonia Napravnik; Katerina Christopoulos; Heidi M Crane; Michael J Mugavero Journal: AIDS Date: 2017-04-24 Impact factor: 4.177
Authors: Seth Himelhoch; David Mohr; Jennifer Maxfield; Sara Clayton; Elyssa Weber; Deborah Medoff; Lisa Dixon Journal: Psychol Health Med Date: 2011-03 Impact factor: 2.423
Authors: Stephanie K Y Choi; Eleanor Boyle; John Cairney; Evan J Collins; Sandra Gardner; Jean Bacon; Sean B Rourke Journal: PLoS One Date: 2016-11-01 Impact factor: 3.240
Authors: Elise Meeder; Vasiliki Matzaraki; Nadira Vadaq; Lisa van de Wijer; André van der Ven; Arnt Schellekens Journal: J Clin Med Date: 2021-11-23 Impact factor: 4.241
Authors: Stephanie K Y Choi; Eleanor Boyle; John Cairney; Sandra Gardner; Evan J Collins; Jean Bacon; Sean B Rourke Journal: PLoS One Date: 2016-06-09 Impact factor: 3.240